← All trials
NCT02662062
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2016
- Primary completion
- Sep 1, 2023
- Completion date
- Jan 1, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Australian and New Zealand Urogenital and Prostate Cancer Trials GroupLead sponsor
- Austin HealthOverall official - principal investigator
- Peter MacCallum Cancer CentreCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.